Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Juniper Pharmaceuticals, Inc. (JNP) on Behalf of Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire
Jul. 06, 2018
NEW YORK, July 06, 2018 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) stockholders concerning the proposed acquisition of the company by Catalent Inc.
Pursuant to the proposed transaction, valued at approximately $5.58B, Juniper shareholders will receive $11.50 in cash for each of their Juniper Pharmaceuticals shares. Our investigation concerns whether the Juniper Pharmaceuticals board of directors failed to adequately shop the Company and obtain the best possible value for its stockholders before entering into a definitive merger agreement with Catalent.
If you own Juniper Pharmaceuticals shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at email@example.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation of Juniper Pharmaceuticals Inc., please go to https://bespc.com/juniper. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com.